PRME - Prime Medicine, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.25
DETAILS
HIGH:
$23.00
LOW:
$12.00
MEDIAN:
$17.00
CONSENSUS:
$17.25
UPSIDE:
480.81%
About Prime Medicine, Inc. (https://www.primemedicine.com)
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Allan Reine | Chief Executive Officer & Director | 1975 | $1,065,389 USD |
| Keith Michael Gottesdiener | Consultant | 1954 | $1,021,968 USD |
| Svetlana Makhni | Chief Financial Officer | 1984 | $924,027 USD |
| Ann L. Lee | Chief Technical Officer | 1962 | $760,041 USD |
| Matthew J. Hawryluk | Chief Business Officer | 1979 | $680,800 USD |
| Jeffrey D. Marrazzo | Executive Chair | 1979 | $140,161 USD |
| Andrew Anzalone | Co-Founder | 1987 | – |
| David R. Liu | Co-Founder & Member of Scientific Advisory Board | – | – |
| Mohammed Asmal | Chief Medical Officer | – | – |
| Niamh Alix | Chief Human Resources Officer | – | – |
| Ryan E. Brown | Chief Legal Officer | 1979 | – |